GC Corp.
Financials
Valuation Metrics
GC Corp.'s Market Cap is ₩4426B. At end of 2025 it was ₩7710B. Ranked #484 of 2,414 in KR market (top 20%), #307 of 781 on KOSPI (top 39%), #52 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 442.63B KRW | KR#484/2,414 Sec#52/231 |
| Revenue | 2.49T KRW | KR#220/2,414 Sec#3/231 |
| Net Income | -151.13B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 4.07T KRW | KR#198/2,414 Sec#4/231 |
| Net Assets | 1.76T KRW | KR#204/2,414 Sec#7/231 |
| Employees | 155 | KR#1,294/2,414 Sec#105/231 |
| Value | ||
| P/B | 0.25x | KR#256/2,414 Sec#10/231 |
| P/S | 0.18x | KR#336/2,414 Sec#3/231 |
| EV/EBITDA | 59.71x | KR#1,393/2,414 Sec#92/231 |
| FCF Yield | -19.56% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -8.57% | KR#1,905/2,414 Sec#141/231 |
| ROA | -3.71% | KR#1,870/2,414 Sec#133/231 |
| Op. Margin | 1.17% | KR#1,488/2,414 Sec#103/231 |
| Revenue Growth | 9.57% | KR#924/2,414 Sec#90/231 |
| Earnings Growth | -168.39% | KR#1,220/2,414 Sec#81/231 |
| Financial Health | ||
| Debt Ratio | 130.71% | KR#1,793/2,414 Sec#200/231 |
| Total Debt | 1.37T KRW | KR#166/2,414 Sec#3/231 |
| FCF | -86.57B KRW | KR#2,121/2,414 Sec#210/231 |
| Cash | 79.66B KRW | KR#551/2,414 Sec#27/231 |
| Current Ratio | 0.96x | KR#1,769/2,414 Sec#175/231 |
| Net Debt/EBITDA | 44.44x | KR#1,476/2,414 Sec#103/231 |
| Dividend | ||
| Div. Yield | 3.29% | KR#605/2,414 Sec#27/231 |
| Div. Growth | -40.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -41.40% | KR#1,798/2,414 Sec#159/231 |
| 1M Return | -5.70% | KR#1,082/2,414 Sec#104/231 |
| From 52W High | -49.47% | KR#1,202/2,414 Sec#98/231 |
| 1Y MDD | -47.35% | KR#871/2,414 Sec#71/231 |
| Trading | ||
| Volume | 68,038 shares | KR#1,166/2,414 Sec#117/231 |
| Trading Value | 620.1M KRW | KR#975/2,414 Sec#105/231 |
| Foreign Own. | 8.20% | KR#543/2,414 Sec#46/231 |
| Per Share | ||
| EPS | -3,107 KRW | KR—/2,414 Sec—/231 |
| BPS | 36,261 KRW | KR#323/2,414 Sec#19/231 |
Company Info
Established in 1967 and headquartered in Yongin, Gyeonggi, Green Cross Holdings transitioned into a holding company in 2001. It oversees a total of 56 domestic and international corporate affiliates, led by Green Cross, primarily in biotechnology and healthcare. The company performs holding company roles such as management strategy and investment asset portfolio management, while actual business operations are handled by its subsidiaries. In 2025, it expanded its business scope by acquiring ABO Holdings to enter the US blood center business and consolidating 15 new companies including Bibros.